Last reviewed · How we verify
Sinbaro-3
Sinbaro-3 is a herbal medicine formulation designed to modulate inflammatory and immune responses, likely through multiple bioactive compounds targeting pain and inflammatory pathways.
Sinbaro-3 is a herbal medicine formulation designed to modulate inflammatory and immune responses, likely through multiple bioactive compounds targeting pain and inflammatory pathways. Used for Musculoskeletal pain and inflammation (Phase 3 indication presumed based on developer).
At a glance
| Generic name | Sinbaro-3 |
|---|---|
| Also known as | Harpagophytum Procumbens |
| Sponsor | Jaseng Hospital of Korean Medicine |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Musculoskeletal Disorders |
| Phase | Phase 3 |
Mechanism of action
As a traditional Korean medicine product from Jaseng Hospital, Sinbaro-3 is composed of herbal ingredients intended to reduce inflammation and pain through multi-target mechanisms. The exact molecular targets are not well-characterized in Western pharmacological literature, but the formulation is designed based on traditional Korean medicine principles to address musculoskeletal and inflammatory conditions.
Approved indications
- Musculoskeletal pain and inflammation (Phase 3 indication presumed based on developer)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sinbaro-3 CI brief — competitive landscape report
- Sinbaro-3 updates RSS · CI watch RSS
- Jaseng Hospital of Korean Medicine portfolio CI